Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally

Company Signs Major New Agreement with Chinese Manufacturer

CORAL SPRINGS, Florida, April 22, 2015 /PRNewswire/ --

The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income.  Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020.  Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)

Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company is pleased to announce they have signed a long-term manufacturing, marketing and distribution agreement with 8E6Tong Private Company Ltd (Tong)., a Singapore-registered company with a manufacturing facility located in Tongxiang, China.   Under the agreement, Tong will be launching its own brand of products using Axxess' patented formula. Tongs products will be sold online, world-wide and in select retail outlets. Axxess Pharma projects minimum sales of $525,000 USD in the first year and $4,308,000 USD in the initial 5 year term of the license.

Read the full AXXE press release at

Tong is focused on the production, marketing, and distribution of health sciences products to improve the quality of life.  The facility has been involved in the application of environmental science and green chemistry since 2010.  "This deal represents a major milestone for Axxess Pharma, and validates the value of our Intellectual Property. Revenues are expected to begin in the third quarter 2015 and accelerate year over year." stated Dr. Bagi President of Axxess Pharma Inc.

 In other nutritional supplement & pharma news and happenings:  GNC (NYSE: GNC) has become the first major retailer of dietary supplements to adopt testing procedures for its herbal brands that exceed Food and Drug Administration standards.  The nationwide retailer recently announced that its Herbal Plus products would be DNA-tested to ensure that the ingredients listed on their labels actually are in the products.  GNC also said it will display notices at stores and on its websites clarifying the products' manufacturing and processing procedures and disclose whether chemicals are used to make them.  Read the full article at

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (NASDAQ: MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company.  Teva's proposal also provides Mylan stockholders with a more attractive alternative to Mylan's proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva's proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan's press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan.

Vitamin Shoppe (NYSE:VSI) earned an average recommendation of "Hold" from the fourteen brokerages last week that are presently covering the company, reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $45.48.  Vitamin Shoppe has a 52-week low of $36.900 and a 52-week high of $49.830. The stock's 50-day moving average is $41.5 and its 200-day moving average is $44.0. The company has a market cap of $1.20 billion and a price-to-earnings ratio of 20.192.  Read the full news at

For the last 35 years, Herbalife Ltd. (NYSE: HLF) - the Los Angeles nutrition and weight-loss company - has sold its products through a network of independent salespeople, but not online.  Now that's changing.  For the first time, Herbalife is giving U.S. customers the option of buying its protein bars, vitamins, teas and powered shake mix on the company's website.  New customers can click a few buttons and order a 30-serving container of Herbalife's top-selling Formula 1 Cookies and Cream flavor shake powder - $47.09 including shipping to a California address.  Read the full article at

Trade-Ideas LLC identified Enzon Pharmaceuticals (NASDAQ: ENZN) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Enzon Pharmaceuticals as such a stock due to the following factors:  ENZN has an average volume over 400,000 shares traded per day. - ENZN has traded 9.9Mil shares on Tuesday. - ENZN is trading over 20 times the normal volume for the stock. - Read the full article at is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at  Follow us on Facebook: and Twitter: 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For this current release sourced by FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Axxess Pharma Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1(954)345-0611